Diabetes and the eye by Thunstrom, V
Diabetes causes a wide spectrum of diseases in and around the 
eye. Diabetic damage is not limited to the lens and retina, but also 
includes other orbital, ocular and neurological complications. The 
WHO estimates that there are 150 million people worldwide living 
with diabetes, and expects this figure to double by 2025. More than 
90% of these patients are type 2 diabetics. According to WHO and 
CDC statistics there are about 7.5 million undiagnosed diabetics 
in the USA.
Orbit and lids
Mucormyces mucor is an anaerobic fungus which is a commensal 
organism in immune-competent individuals. In diabetic patients 
with immunoparesis it can cause an invasive life-threatening 
infection. It invades endothelial cells and causes necrotising 
vasculitis. The patient may present with orbital cellulitis. The 
hallmark of this disease is a black eschar on the eyelids or palate. 
A high index of suspicion and prompt referral to an ear, nose and 
throat specialist or an ophthalmologist are required. A biopsy or pus 
swab will confirm the diagnosis. Treatment is surgical débridement 
to the border of viable tissue and intravenous amphotericin B. 
Hyperbaric oxygen may also be beneficial.
Cornea
Neurotrophic keratopathy
Corneal sensation is supplied by the first branch of the trigeminal 
nerve and may be affected in long-standing diabetics. This 
predisposes the patient to recurrent corneal erosions and infectious 
keratitis.
Infectious keratitis
This may occur in a neurotrophic cornea. As part of the 
immunoparesis, or because of microtrauma, diabetics are 
predisposed to fungal keratitis (Fig. 1), especially with Candida 
spp. The patient presents with a gradual onset of a painful eye, 
with conjunctival injection and a white, well-circumscribed 
corneal infiltrate. There may be a pus level in the anterior chamber 
(hypopyon). The diagnosis is made by an ophthalmologist on 
corneal scraping and culture of the specimen. Antifungal treatment 
is with amphotericin B or fluconazole. 
Lens
Refractive instability
Fluctuations in blood glucose level may cause swelling of the lens 
because of osmotic changes. Patients may be aware of intermittent 
blurring in vision as their refractive status may fluctuate until blood 
glucose levels are stabilised. This may occur in newly diagnosed 
diabetics or in those whose blood glucose levels are unstable.
Cataract
Diabetics are prone to pre-senile cataract formation (Fig. 2). Before 
cataract surgery the retinal status must be evaluated thoroughly, 
as both diabetic maculopathy and diabetic retinopathy may be 
worsened by  cataract surgery. 
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Fig. 1. Fungal keratitis.
Fig. 2. Cataract.
  CME  October  2007  Vol.25  No.10
pg 476-478.indd   476 10/11/07   4:19:33 PM
477 
D iab etes
Small-incision phacoemulsification is the 
technique of choice, with careful follow-up 
of retinopathy status and macular oedema.
Diabetic retinopathy
This is by far the most important form of 
ocular complication in diabetes. Patients 
must be well educated at an early stage 
of their disease, so that the appropriate 
interventions may be performed timeously. 
When patients start complaining of visual 
symptoms, they often already have serious 
eye complications and visual recovery is not 
always possible.
Diabetic retinopathy may be present at 
diagnosis in type 2 diabetics, but nearly 
all type 1 diabetics have some form of 
retinopathy by 10 years.1 Diabetic women 
who are contemplating pregnancy should be 
seen before falling pregnant, as pregnancy 
accelerates diabetic retinopathy, and laser 
treatment should be commenced timeously. 
Pathogenesis
Diabetic retinopathy is categorised into 
either diabetic maculopathy, or proliferative 
changes (Fig. 3). 
Maculopathy is the most common cause 
of moderate to severe visual loss, while 
proliferative diabetic retinopathy (PDR) 
is the most common cause of severe, 
irreversible visual loss.
Damage is on a microvascular level, and 
mirrors damage to kidney, heart and 
limbs. Loss of pericytes leads to loss of 
vessel integrity, with the formation of 
microaneurysms. These are prone to leakage 
and form the basis of diabetic maculopathy, 
mostly manifested as intraretinal oedema 
and hard exudates that appear as hard, yellow 
glistening bodies. Microvascular occlusion 
occurs secondary to sorbitol damage and 
increased erythrocyte adhesion. This leads to 
retinal ischaemia and production of vascular 
endothelial growth factor (VEGF). This in 
turn leads to retinal neovascularisation, 
vitreous haemorrhage, gliosis and traction 
retinal detachment. ‘Cotton wool’ spots are 
fluffy white areas of the retinal nerve fibre 
layer that represent micro-infarcts. 
Screening
It is essential that all diabetics are educated 
about ocular complications of their disease. 
Screening before onset of symptoms is 
the only way to manage problems at the 
appropriate stage. All type 2 diabetics 
should be screened at diagnosis and yearly 
thereafter. This is due to possible delayed 
diagnosis of the onset of diabetes. Patients 
may even present with vitreous haemorrhage 
and not be aware that they are diabetic. Type 
1 diabetics should be screened 10 years after 
diagnosis and yearly thereafter.
With the use of non-mydriatic fundus 
cameras fundal pictures can be gathered 
from a large diabetic population and can 
then be screened by a skilled individual. 
Those with diabetic retinopathy and those 
ungradable because of media opacity should 
be referred to an ophthalmologist. The Early 
Treatment Diabetic Retinopathy Study 
showed that early laser treatment decreased 
the risk of visual loss by 90%.2
The aim of laser treatment in proliferative 
diabetic retinopathy is to induce regression 
of retinal neovascularisation, and may be 
performed over a number of sessions. 
Maculopathy may be of the exudative or 
ischaemic type. Ischaemic maculopathy is 
diagnosed on fluorescein angiogram (Fig. 
4), where there is loss of retinal capillaries 
supplying the fovea. The degree of visual loss 
correlates with that of vascular fall-out seen 
on angiography, and is irreversible.
Exudative maculopathy is diagnosed by 
the loss of normal macular light reflex and 
presence of haemorrhages and exudates 
around the macula.
The use of argon laser for maculopathy 
is aimed at stabilising vision, which may 
improve in 20 - 30% of patients. Laser 
treatment is applied in a C-shaped grid 
around the fovea, or else focal burns are 
applied to leaking microaneurysms. A 
fluorescein angiogram may be useful in 
identifying leaking aneurysms, in order that 
the aneurysms may be treated with laser. 
Optical coherence tomography
Optical coherence tomography (OCT) is a 
new imaging technique using near infrared 
frequency light to obtain an almost live 
histological picture of the retina. It can also 
quantify retinal thickness exactly. 
It is essential 





Fig. 3.  Spectrum of changes in diabetic retinopathy in a patient with advanced proliferative 
changes and macular oedema.
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It is essential that all diabetics are educated abou ocular complicati ns of their disease.
Screening before the onset of symptoms is the only way to manag problems at the
appropriate stage. All type 2 diabetics should be screened at diagnosis and yearly thereafter.
This is due to possible delayed diagnosis of the onset of diabetes. Patients may even present
with vitreous haemorrhage and not be aware that they are diabetic. Type 1 diabetics should
be screened 10 years after diagnosis and yearly thereafter.
With the use of non-mydriatic fundus cameras fundal pictures can be gathered from a large
diabetic population and can then be screened by a skilled individ al. All those having diabetic
retinopathy or those who are ungradable due to media opacity, should be referred to an
ophthalmologist. The Early Treatment Diabetic Retinopathy Study showed that early laser
treatment decreased the risk of visual loss by 90%.2
Fig. 4. Fluorescein angiogram showing late-phase macular oedema.
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The aim of laser in proliferative diabetic retinopathy is to induce regression of retinal
neovascularization, and may be performed over a number of sessions.
Maculopathy may be of the exudative or ischaemic type. Ischaemic maculopathy is diagnosed
on fluorescein angiogram, w ere ther is a loss of the ret nal capillari s supplying the fovea.





Fig.4 Fluorescein angiogram showing late phase macular edema
Exudative maculopathy is diagnosed by the loss of the normal macular light reflex, and the
presence of hemorrhages and exudates around the macula.
The use of Argon laser for maculopathy is aimed at stabilizing vision; vision may improve in
about 20-30% of patients. Laser treatment is applied in a C-shape grid around the fovea, or
October  2007  Vol.25  No.10  CME
pg 476-478.indd   477 10/11/07   4:19:36 PM
478
D iab etes
This is very useful in following up cases 
of diabetic macular oedema (DME) to 
assess whether or not retinal thickness has 
responded to laser treatment.  
Another essential cornerstone in the 
prevention of visual loss and systemic end-
organ damage is good, long-term control 




This is a long-acting steroid preparation 
which is delivered to the posterior segment 
of the eye by intravitreal injection. The 
main indication is DME non-responsive to 
conventional argon laser treatment. It has 
been shown to decrease macular thickness 
for about 3 months.3 It may be more 
efficaceous if given early during the course 
of the oedema, before the onset of chronic 
ultrastructural changes. 
Bevacizumab
Bevacizumab is an antibody fragment to 
VEGF and has potent antiproliferative and 
antipermeability activity. It was developed 
for use in patients with metastatic 
colorectal cancer. Its greatest ocular use 
to date has been for exudative age-related 
macular degeneration. Its application in 
diabetes is mainly related to DME, where 
its antipermeability effects are used to 
reduce macular thickness. Even though it is 
effective for only a short time, it shows much 
promise.
The future …
Widespread screening programmes need to 
be instituted where non-mydriatic pictures 
are taken and screened by a suitably qualified 
person. The future will probably centre 
around medical treatment, with less need 
for laser treatment, with anti-VEGF agents 
currently showing the most promise.
Surgical treatments
Vitreous haemorrhage 
Unfortunately, there are still many patients 
with PDR who either have very aggressive 
disease or who present late and develop 
complications requiring vitrectomy. 
Vitreous haemorrhage presents in varying 
degrees of severity – up to the most severe 
where the fundus is not visible. These 
patients complain of sudden, but painless, 
severe loss of vision. They must be referred 
immediately to exclude retinal detachment 
(RD). A short period of observation may be 
warranted, whereafter pars plana vitrectomy 
may be performed, the blood is cleared and 
laser treatment applied from inside the eye.
Tractional retinal detachment 
Tractional RD occurs when retinal 
neovascularisation, with its associated fibrous 
proliferation and vitreous haemorrhage, 
organises into a gliotic membrane overlying 
the retina and undergoes contraction. This 
membrane then elevates the retina at various 
points. Surgery is indicated if the traction 
is very high, if the macula is detached or 
if the traction on the macula is direct. The 
aim of surgery then is to clear the vitreous 
gel, resect the gliotic membrane, and apply 
endolaser as required.
Other retinal abnormalities
Branch retinal vein occlusion 
(BRVO)/central retinal vein 
occlusion (CRVO)
As diabetics usually have elevated blood 
pressure, high erythrocyte adhesion and 
high cholesterol levels, they are more 
prone to BRVO or CRVO. Patients typically 
present with sudden onset of blurred vision, 
which may be severe. The fundus shows 
dilated tortuous veins, with scattered flame-
shaped retinal haemorrhages. Ophthalmic 
assessment is required for diagnosis. Fundus 
fluorescein angiography may be indicated 
to assess the degree of retinal ischaemia. 
Patients may require laser therapy, to treat 
neovascularisation or macular oedema.
Cranial nerve palsies
As mentioned above diabetics tend to 
have a host of problems, including raised 
cholesterol levels and hypertension. As 
such they may be prone to vasculopathic 
complications. A micro-infarct of one of 
the cranial nerves supplying the extraocular 
muscles (3rd, 4th or 6th) may cause double 
vision. A full neurological examination is 
required, including an examination of all the 
cranial nerves. Once it has been confirmed 
that there is only a mononeuropathy present, 
a period of observation is warranted. Full 
recovery usually occurs after 3 - 6 months. 
During this time, one of the eyes can be 
covered with a patch to prevent troublesome 
diplopia. If at any time there is progression 
of the palsy, or if the patient does not fully 
recover, it is warranted for the patient to 
undergo neuro-imaging to exclude any 
other intracranial process.
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In a nutshell 
•    Diabetes can cause severe, irreversible 
visual loss.
•    The incidence of diabetes is on the 
rise.
•    Early education and screening are 
mandatory to prevent visual loss.
•    Good metabolic control is vital to pre-
vent end-organ damage.
•    Type 2 diabetics may have retinopa-
thy at the time of diagnosis of their 
diabetes.
•    Older diabetics are vasculopaths and 
prone to micro-infarcts.
•    Decreased humoral immunity makes 
diabetics prone to severe corneal and 
orbital infections.
•    Diabetic patients wishing to fall 
pregnant should have their eyes evalu-
ated before pregnancy.
•    Visual loss may be prevented by early 
laser treatment.
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